Long-acting injectable buprenorphine for opioid use disorder: A systematic review of impact of use on social determinants of health.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of substance abuse treatment"
DOI: 10.1016/j.jsat.2022.108776
Abstract: OBJECTIVES This systematic review synthesizes evidence on both the effects and perspectives of the use of novel long-acting injectable buprenorphine (LAIB) as part of medication-assisted treatment (MAT) and its impact on social determinants of health… read more here.
Keywords: injectable buprenorphine; social determinants; acting injectable; systematic review ... See more keywords
Exploring the effectiveness of a regional nurse practitioner led, long-acting injectable buprenorphine-based model of care for opioid use disorder.
Sign Up to like & getrecommendations! Published in 2023 at "International journal of mental health nursing"
DOI: 10.1111/inm.13154
Abstract: The introduction of long-acting injectable buprenorphine preparations for opioid use disorder has been widely heralded as a breakthrough treatment, with several studies indicating positive results when using these medications. In many locations, nurse practitioners prescribe,… read more here.
Keywords: practitioner led; acting injectable; nurse practitioner; long acting ... See more keywords
Long-acting injectable buprenorphine – ‘best practice’ opioid agonist therapy for Australian prisoners
Sign Up to like & getrecommendations! Published in 2022 at "Australasian Psychiatry"
DOI: 10.1177/10398562211059086
Abstract: Objective To consider opioid agonist therapy in prisons. Conclusions Given the substantial risks of substance misuse by prisoners, long-acting injectable buprenorphine should be adopted as ‘best practice’ treatment in Australian prison populations. read more here.
Keywords: long acting; acting injectable; best practice; agonist therapy ... See more keywords